Header Logo

Connection

MANDEEP BAJAJ to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications MANDEEP BAJAJ has written about Diabetes Mellitus, Type 2.
MANDEEP BAJAJ
Connection Strength
4.983
Diabetes Mellitus, Type 2
  1. Genetic prediction of type 2 diabetes using deep neural network. Clin Genet. 2018 04; 93(4):822-829.
    View in: PubMed
    Score: 0.297
  2. Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. J Diabetes Complications. 2017 02; 31(2):291-294.
    View in: PubMed
    Score: 0.269
  3. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014 Oct; 28(5):447-57.
    View in: PubMed
    Score: 0.234
  4. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med. 2014 Dec; 31(12):1505-14.
    View in: PubMed
    Score: 0.231
  5. The regulation of muscle protein turnover in diabetes. Int J Biochem Cell Biol. 2013 Oct; 45(10):2239-44.
    View in: PubMed
    Score: 0.215
  6. DPP-4 inhibitors and atherosclerosis: the promise. Atherosclerosis. 2013 Apr; 227(2):224-5.
    View in: PubMed
    Score: 0.208
  7. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis. 2012 Jul; 223(1):204-8.
    View in: PubMed
    Score: 0.199
  8. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011 Dec; 54(12):3093-100.
    View in: PubMed
    Score: 0.190
  9. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011 Dec; 19(12):2310-5.
    View in: PubMed
    Score: 0.186
  10. Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. Metab Syndr Relat Disord. 2010 Oct; 8(5):459-63.
    View in: PubMed
    Score: 0.178
  11. Insulin clamp-derived measurements of insulin sensitivity and insulin secretion in lean and obese asian type 2 diabetic patients. Metab Syndr Relat Disord. 2010 Apr; 8(2):113-8.
    View in: PubMed
    Score: 0.172
  12. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010 Apr; 95(4):1916-23.
    View in: PubMed
    Score: 0.170
  13. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous souffl?. Metab Syndr Relat Disord. 2009 Apr; 7(2):79-81.
    View in: PubMed
    Score: 0.160
  14. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 2007 Aug; 50(8):1723-31.
    View in: PubMed
    Score: 0.141
  15. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother. 2006 Jun; 7(8):1055-64.
    View in: PubMed
    Score: 0.132
  16. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes. 2005 Nov; 54(11):3148-53.
    View in: PubMed
    Score: 0.126
  17. Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care. 2025 Feb 01; 48(2):177-181.
    View in: PubMed
    Score: 0.120
  18. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab. 2004 Sep; 89(9):4649-55.
    View in: PubMed
    Score: 0.117
  19. Impaired mitochondrial activity and insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004 Jun 03; 350(23):2419-21; author reply 2419-21.
    View in: PubMed
    Score: 0.115
  20. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord. 2004 Jun; 28(6):783-9.
    View in: PubMed
    Score: 0.115
  21. Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep. 2004 Jun; 4(3):213-8.
    View in: PubMed
    Score: 0.115
  22. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Jan; 89(1):200-6.
    View in: PubMed
    Score: 0.111
  23. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003 Jun; 52(6):1364-70.
    View in: PubMed
    Score: 0.107
  24. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol. 2003 May-Jun; 10(3):311-23.
    View in: PubMed
    Score: 0.106
  25. Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes. 2002 Oct; 51(10):3043-8.
    View in: PubMed
    Score: 0.102
  26. Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. Cardiovasc Drugs Ther. 2020 12; 34(6):835-848.
    View in: PubMed
    Score: 0.088
  27. DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
    View in: PubMed
    Score: 0.082
  28. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
    View in: PubMed
    Score: 0.075
  29. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
    View in: PubMed
    Score: 0.074
  30. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
    View in: PubMed
    Score: 0.070
  31. Dickkopf-1 (DKK1) phosphatase and tensin homolog on chromosome 10 (PTEN) crosstalk via microRNA interference in the diabetic heart. Basic Res Cardiol. 2013 May; 108(3):352.
    View in: PubMed
    Score: 0.053
  32. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
    View in: PubMed
    Score: 0.052
  33. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
    View in: PubMed
    Score: 0.051
  34. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther. 2008 11; 16(11):1805-12.
    View in: PubMed
    Score: 0.039
  35. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab. 2007 Jun; 292(6):E1775-81.
    View in: PubMed
    Score: 0.035
  36. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab. 2005 Feb; 90(2):1100-5.
    View in: PubMed
    Score: 0.030
  37. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.029
  38. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep; 89(9):4312-9.
    View in: PubMed
    Score: 0.029
  39. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004 Sep; 287(3):E537-46.
    View in: PubMed
    Score: 0.028
  40. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia. 2004 May; 47(5):816-20.
    View in: PubMed
    Score: 0.028
  41. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003 Oct; 52(10):2461-74.
    View in: PubMed
    Score: 0.027
  42. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2002 Jun; 282(6):E1360-8.
    View in: PubMed
    Score: 0.025
  43. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care. 1998 Aug; 21(8):1330-8.
    View in: PubMed
    Score: 0.019
  44. miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. Diabetes. 2018 12; 67(12):2541-2553.
    View in: PubMed
    Score: 0.019
  45. Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Mol Endocrinol. 2015 Sep; 29(9):1320-33.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.